HCPCS Level II code J1413 identifies a therapeutic-dose injection of delandistrogene moxeparvovec-rokl, a gene therapy delivered as a single therapeutic dose. This code matters nationally because it applies to a high-cost, specialized biologic therapy that typically requires facility resources, care coordination, and payer medical review. Its use affects hospital outpatient billing, coverage determinations, and specialty pharmacy or infusion workflows.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J1413 represents clinically and administratively, summaries of common coverage and billing considerations across major payers, and the types of benchmarks and policy updates that influence reimbursement and utilization management. The publication also provides clinical context for therapy administration, typical sites of service, and common modifiers used with high-cost therapeutic-dose injections. Where specific inputs were not provided, the summary notes that data are not available in the input.